SIX · LONN.SW
Lonza Group AG
CHF 640.80+CHF 11.00 (+1.75%)
Lonza Group AG’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
Loading market information…
HKSE · 2269.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 02:19 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
WuXi Biologics (Cayman) Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.28% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
WuXi Biologics (Cayman) Inc.’s next earnings report is currently expected on Mar 23, 2027, with estimated earnings per share of HK$0.86. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow WuXi Biologics (Cayman) Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | Mar 27, 2024 | HK$0.29+4.87% vs estimate | HK$9.45B-16.76% vs estimate |
|---|
| Q2 2023 | Aug 23, 2023 | HK$0.56-5.05% vs estimate | HK$9.18B+4.36% vs estimate |
|---|
| Q4 2022 | Mar 23, 2023 | HK$0.49+14.32% vs estimate | HK$9.18B+1.6% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CHF 640.80+CHF 11.00 (+1.75%)
Lonza Group AG’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
CN¥143.59+CN¥0.70 (+0.49%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 17.29% below the high.
₩1,421,000+₩55,000 (+4.03%)
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 28.43% below the high.
HK$67.35-HK$0.55 (-0.81%)
WuXi XDC Cayman Inc’s quoted price sits in the upper half of its reported 52-week range, 21.32% below the high.
HK$36.70-HK$1.00 (-2.65%)
Genscript Biotech Corporation’s quoted price sits in the upper half of its reported 52-week range, 25.8% below the high.
CN¥133.10-CN¥1.11 (-0.83%)
Asymchem Laboratories (Tianjin) Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.45% below the high.
CN¥44.72-CN¥1.06 (-2.32%)
Joinn Laboratories(China)Co.,Ltd.’s quoted price sits in the upper half of its reported 52-week range, 19.68% below the high.
HK$6.10-HK$0.12 (-1.93%)
XtalPi Holdings Ltd’s quoted price sits in the lower half of its reported 52-week range, 57.28% below the high.
